arna-10q_20180331.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to

Commission File Number: 000-31161

 

ARENA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

23-2908305

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

6154 Nancy Ridge Drive, San Diego, CA

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

858.453.7200

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes      No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes      No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  (Do not check if a small reporting company)

  

Small reporting company

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No

The number of shares of common stock outstanding as of the close of business on May 4, 2018:

 

Class

 

Number of Shares Outstanding

Common Stock, $0.0001 par value

 

49,234,094

 

 

 

 


 

ARENA PHARMACEUTICALS, INC.

INDEX

 

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements

1

 

Condensed Consolidated Balance Sheets - As of March 31, 2018, and December 31, 2017

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss - Three Months Ended March 31, 2018, and 2017

2

 

Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2018, and 2017

3

 

Notes to Unaudited Condensed Consolidated Financial Statements

4

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

24

PART II—OTHER INFORMATION

Item 1.

Legal Proceedings

25

Item 1A.

Risk Factors

27

Item 6.

Exhibits

50

Signatures

51

 

 

TRADEMARKS AND CERTAIN TERMS

Arena Pharmaceuticals ® and Arena ® are registered service marks of Arena. Any other brand names or trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.

In this Quarterly Report on Form 10-Q, “Arena Pharmaceuticals,” “Arena,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and our wholly owned subsidiaries on a consolidated basis, unless the context otherwise provides. “APD” is an abbreviation for Arena Pharmaceuticals Development.

 

 

i


 

PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements.

ARENA PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

516,141

 

 

$

158,837

 

Short-term investments, available-for-sale

 

 

112,980

 

 

 

88,240

 

Accounts receivable

 

 

3,306

 

 

 

2,357

 

Insurance recovery receivable

 

 

12,025

 

 

 

12,025

 

Prepaid expenses and other current assets

 

 

5,409

 

 

 

2,681

 

Assets of disposal group held for sale

 

 

 

 

 

17,140

 

Total current assets

 

 

649,861

 

 

 

281,280

 

Investments, available-for-sale

 

 

 

 

 

24,242

 

Land, property and equipment, net

 

 

29,507

 

 

 

30,131

 

Other non-current assets

 

 

6,100

 

 

 

3,622

 

Total assets

 

$

685,468

 

 

$

339,275

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and other accrued liabilities

 

$

9,111

 

 

$

7,916

 

Accrued clinical and preclinical study fees

 

 

4,817

 

 

 

7,706

 

Accrued litigation settlement

 

 

24,000

 

 

 

24,000

 

Current portion of deferred revenues

 

 

800

 

 

 

1,110

 

Current portion of lease financing obligations

 

 

3,799

 

 

 

4,000

 

Liabilities of disposal group held for sale

 

 

 

 

 

27,595

 

Total current liabilities

 

 

42,527

 

 

 

72,327

 

Other long-term liabilities

 

 

1,002

 

 

 

989

 

Deferred revenues, less current portion

 

 

815

 

 

 

1,067

 

Lease financing obligations, less current portion

 

 

56,989

 

 

 

57,748

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

2,087,487

 

 

 

1,698,543

 

Accumulated other comprehensive loss

 

 

(241

)

 

 

(1,216

)

Accumulated deficit

 

 

(1,503,116

)

 

 

(1,490,187

)

Total stockholders' equity

 

 

584,135

 

 

 

207,144

 

Total liabilities and stockholders' equity

 

$

685,468

 

 

$

339,275

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

1


 

ARENA PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2018

 

 

2017

 

Revenues:

 

 

 

 

 

 

 

 

Collaboration and other revenue

 

$

1,028

 

 

$

1,660

 

Royalty revenue

 

 

727

 

 

 

 

Total revenues

 

 

1,755

 

 

 

1,660

 

Operating Costs and Expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

21,573

 

 

 

15,344

 

General and administrative

 

 

11,151

 

 

 

7,520

 

Total operating costs and expenses

 

 

32,724

 

 

 

22,864

 

Loss from operations

 

 

(30,969

)

 

 

(21,204

)

Interest and Other Income (Expense):

 

 

 

 

 

 

 

 

Interest income

 

 

774

 

 

 

34

 

Interest expense

 

 

(1,472

)

 

 

(1,570

)

Other income

 

 

534

 

 

 

189

 

Total interest and other expense, net

 

 

(164

)

 

 

(1,347

)

Loss from continuing operations

 

 

(31,133

)

 

 

(22,551

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

54

 

Net loss

 

 

(31,963

)

 

 

(22,497

)

Less net loss attributable to noncontrolling interest in

   consolidated variable interest entity

 

 

 

 

 

444

 

Net loss attributable to stockholders of Arena

 

$

(31,963

)

 

$

(22,053

)

 

 

 

 

 

 

 

 

 

Amounts attributable to stockholders of Arena:

 

 

 

 

 

 

 

 

Loss from continuing operations

 

 

(31,133

)

 

 

(22,107

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

54

 

 

 

$

(31,963

)

 

$

(22,053

)

 

 

 

 

 

 

 

 

 

Net loss attributable to stockholders of Arena per share, basic and diluted:

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.78

)

 

$

(0.90

)

Discontinued operations

 

 

(0.02

)

 

 

 

 

 

$

(0.80

)

 

$

(0.90

)

 

 

 

 

 

 

 

 

 

Shares used in calculating net loss attributable to stockholders of

   Arena per share, basic and diluted:

 

 

39,996

 

 

 

24,482

 

 

 

 

 

 

 

 

 

 

Comprehensive Loss:

 

 

 

 

 

 

 

 

Net loss

 

$

(31,963

)

 

$

(22,497

)

Foreign currency translation gain

 

 

17

 

 

 

804

 

Unrealized loss on available-for-sale investments

 

 

(144

)

 

 

 

Comprehensive loss

 

 

(32,090

)

 

 

(21,693

)

Less comprehensive loss attributable to noncontrolling interest in consolidated variable interest entity

 

 

 

 

 

444

 

Comprehensive loss attributable to stockholders of Arena

 

$

(32,090

)

 

$

(21,249

)

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

 

2


 

ARENA PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2018

 

 

2017

 

Operating Activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(31,963

)

 

$

(22,497

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

(Income) loss from discontinued operations

 

 

830

 

 

 

(54

)

Depreciation and amortization

 

 

949

 

 

 

1,110

 

Share-based compensation

 

 

4,033

 

 

 

1,771

 

Amortization of prepaid financing costs

 

 

28

 

 

 

34

 

Amortization of original issue discounts, net of premiums, on available-for-sale

      investments

 

 

(172

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

661

 

 

 

12,245

 

Prepaid expenses and other assets

 

 

613

 

 

 

(622

)

Payables and accrued liabilities

 

 

(3,438

)

 

 

(3,204

)

Deferred revenues

 

 

(446

)

 

 

(1,106

)

Other long-term liabilities

 

 

(274

)

 

 

(12

)

Net cash used in operating activities - continuing operations

 

 

(29,179

)

 

 

(12,335

)

Net cash used in operating activities - discontinued operations

 

 

(601

)

 

 

(3,922

)

Net cash used in operating activities

 

 

(29,780

)

 

 

(16,257

)

Investing Activities:

 

 

 

 

 

 

 

 

Purchases of available-for-sale investments

 

 

(25,477

)

 

 

 

Proceeds from sale and maturity of available-for-sale investments

 

 

25,005

 

 

 

 

Purchases of property and equipment

 

 

(325

)

 

 

(13

)

Other non-current assets

 

 

(2

)

 

 

(2

)

Net cash used in investing activities - continuing operations

 

 

(799

)

 

 

(15

)

Net cash provided by investing activities - discontinued operations

 

 

2,990

 

 

 

60

 

Net cash provided by investing activities

 

 

2,191

 

 

 

45

 

Financing Activities:

 

 

 

 

 

 

 

 

Principal payments on lease financing obligations

 

 

(960

)

 

 

(816

)

Proceeds from issuance of common stock, net

 

 

385,256

 

 

 

5,267

 

Net cash provided by financing activities

 

 

384,296

 

 

 

4,451

 

Effect of exchange rate changes on cash

 

 

597

 

 

 

578

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

357,304

 

 

 

(11,183

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

159,700

 

 

 

91,575

 

Cash, cash equivalents and restricted cash at end of period

 

$

517,004

 

 

$

80,392

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

3


 

ARENA PHARMACEUTICALS, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Arena Pharmaceuticals, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission, or SEC, from which we derived our condensed consolidated balance sheet as of December 31, 2017. The accompanying condensed consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

In order to further focus our efforts and resources on our strategic objectives of developing our pipeline drug candidates, on March 9, 2018, we entered into an Asset Purchase Agreement, or Sale Agreement, with Siegfried Pharma AG and Siegfried AG, (collectively and individually, Siegfried). Under the Sale Agreement, we agreed to sell and assign to Siegfried, and Siegfried agreed to purchase and assume from Arena GmbH, certain drug product finishing facility assets and know-how, including fixtures, equipment, other personal property and real estate assets located in Zofingen, Switzerland and related contracts and certain related liabilities, or collectively, the Manufacturing Operations. We refer to this transaction as the Siegfried Transaction. The Siegfried Transaction was completed on March 31, 2018. In connection with the Siegfried Transaction, all of Arena GmbH’s approximately 50 employees transferred to Siegfried. We have excluded from our continuing operations for all periods presented in this report revenues and expenses associated with the disposed Manufacturing Operations, which are reported as discontinued operations. See Note 2 for additional information on the Manufacturing Operations.

Beacon Discovery, Inc., or Beacon, is a variable interest entity in which we had a controlling financial interest until December 2017. The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2017. We deconsolidated Beacon in December 2017 (see Note 13).

On June 14, 2017, we filed a certificate of amendment to our certificate of incorporation with the Secretary of State of the state of Delaware to effect a one-for-ten reverse split of our issued and outstanding common stock. The accompanying condensed consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options exercisable for common stock, restricted stock units, performance restricted stock units, and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. Concurrent with the reverse stock split we effected a reduction in the number of authorized shares of common stock from 367,500,000 shares to 73,500,000 shares.

Liquidity.

As of March 31, 2018, we had cash, cash equivalents and available-for-sale investments of approximately $629.1 million. We believe our cash and cash equivalents, and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months.

We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our existing collaborations, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions.

4


 

Changes in Accounting Policies - Revenue Recognition.

Effective January 1, 2018, we adopted Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, issued by the Financial Accounting Standards Board. As a result, we have changed our accounting policy for revenue recognition as detailed below.

We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.

We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  

The cumulative impact to our accumulated deficit balance at January 1, 2018 as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.

The following table summarizes the impacts of adopting ASC 606 on our condensed consolidated financial statements as of and for the three months ended March 31, 2018, in thousands.

 

 

 

Impact of Changes in Accounting Policies

 

Three months ended March 31, 2018

 

As reported

 

 

Adjustments

 

 

Balances without adoption of ASC 606

 

Collaboration and other revenue

 

$

1,028

 

 

$

59

 

 

$

1,087

 

Royalty revenue

 

 

727

 

 

 

262

 

 

 

989

 

Total revenue

 

 

1,755

 

 

 

321

 

 

 

2,076

 

Loss from operations

 

 

(30,969

)

 

 

321

 

 

 

(30,648

)

Loss from continuing operations

 

 

(31,133

)

 

 

1,469

 

 

 

(29,664

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

13,660

 

 

 

12,830

 

Net loss

 

 

(31,963

)

 

 

15,129

 

 

 

(16,834

)

Net loss attributable to stockholders of Arena

 

 

(31,963

)

 

 

15,129

 

 

 

(16,834

)

 

 

 

 

 

 

 

 

 

 

 

 

 

As of March 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

5,409

 

 

$

(1,152

)

 

$

4,257

 

Total current assets

 

 

649,861

 

 

 

(1,152

)

 

 

648,709

 

Other non-current assets

 

 

6,100

 

 

 

(2,694

)

 

 

3,406

 

Total assets

 

 

685,468

 

 

 

(3,846

)

 

 

681,622

 

Current portion of deferred revenues

 

 

800

 

 

 

5

 

 

 

805

 

Total current liabilities

 

 

42,527

 

 

 

5

 

 

 

42,532

 

Deferred revenues, less current portion

 

 

815

 

 

 

52

 

 

 

867

 

Accumulated deficit

 

 

(1,503,116

)

 

 

(3,903

)

 

 

(1,507,019

)

Total stockholders' equity

 

 

584,135

 

 

 

(3,903

)

 

 

580,232

 

Total liabilities and stockholders' equity

 

 

685,468

 

 

 

(3,846

)

 

 

681,622

 

 

Our revenues to date have been generated primarily through collaboration agreements. Our collaboration agreements frequently contain multiple elements including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments. Our customers

5


 

include Everest Medicines Limited, Eisai Inc. and Eisai Co., Ltd., or collectively, Eisai, Axovant Sciences GmbH, or Axovant, Boehringer Ingelheim International GmbH, or Boehringer Ingelheim, and Siegfried.  

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts collected on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:

i) Identify the contract with a customer. We consider the terms and conditions of our collaboration agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.

ii) Identify the performance obligations in the contract. Performance obligations in our collaboration agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.

 iii) Determine the transaction price. We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration agreements contain consideration payable to our customer or a significant financing component.

 iv) Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price.

 v) Recognize revenue when or as we satisfy a performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services.

Performance Obligations.

The following is a description of principal goods and services from which we generate revenue.

 

Intellectual property licenses

We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation. Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.

 

Intellectual property sales

We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer.

 

Research, development and regulatory services

6


 

We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

 

Product manufacturing

We generate revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products are generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 2). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.

Contracts with Multiple Performance Obligations.

Most of our collaboration agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the development and clinical trials.

Variable Consideration.

Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.

Due to uncertainty associated with achievement of the development and regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur.

Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

Disaggregation of Revenue.

We operate in one reportable business segment. We provide goods and services to our customers in collaboration agreements pursuant to various geographical markets. In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands.

 

7


 

Customers

 

Three months ended March 31, 2018

 

Eisai

 

$

2,228

 

Siegfried

 

 

942

 

Axovant

 

 

568

 

Boehringer Ingelheim

 

 

460

 

Other

 

 

64

 

    Total

 

$

4,262

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

Goods and services transferred over time

 

$

1,755

 

Goods and services transferred at a point in time

 

 

2,507

 

    Total

 

$

4,262

 

 

 

 

 

 

Classification

 

 

 

 

Revenue from continuing operations

 

$

1,755

 

Revenue reported under discontinued operations

 

 

2,507

 

    Total

 

$

4,262

 

 

Contract Assets and Contract Liabilities.

We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced. The current portion of contract assets is included in prepaid expenses and other current assets in the condensed consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the condensed consolidated balance sheet. As of January 1, 2018, we recorded a contract asset of $4.1 million, of which $1.4 million is classified as current and $2.7 million is classified as non-current, related to future royalties associated with intellectual property patents previously sold to a customer which do not qualify for the royalty exception in ASC 606. We estimated the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any future changes to this estimate will be recorded as an adjustment to revenue in the period in which the change in estimate is made.  

Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract.

The following table provides detail of changes in our contract assets and deferred revenues, in thousands. The deferred revenue balances as of December 31, 2017, presented in the following table include balances classified as liabilities of disposal group held for sale:

 

 

 

Contract Assets

- Current

 

 

Contract Assets -

Non-Current

 

 

Current Portion of Deferred Revenues

 

 

Deferred Revenues, Less Current Portion

 

Balances at December 31, 2017

 

$

 

 

$

 

 

$

26,560

 

 

$

1,067

 

ASC 606 implementation adjustments

 

 

7,527

 

 

 

2,694

 

 

 

(25,526

)

 

 

(40

)

Collections on contract assets

 

 

(1,977

)

 

 

 

 

 

 

 

 

 

Impact of the disposal of the Manufacturing

     Operations (see Note 2)

 

 

(4,543

)

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

145

 

 

 

 

 

 

 

 

 

 

Recognized as revenue during the period

 

 

 

 

 

 

 

 

(234

)

 

 

(212

)

Balances at March 31, 2018

 

$

1,152

 

 

$

2,694

 

 

$

800

 

 

$

815

 

Cost to Obtain and Fulfill a Contract.

We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.

Remaining Performance Obligations.

8


 

The following table provides detail of estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration agreements as of March 31, 2018, in thousands:

 

 

 

As of March 31, 2018

 

Rest of 2018

 

$

1,969

 

2019

 

 

2,030

 

2020

 

 

658

 

2021 and thereafter

 

 

 

    Total

 

$

4,657

 

Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future royalties and sales-based milestones is not included in the table above.

Recent Accounting Pronouncements.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. ASU No. 2016-01 supersedes and amends the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment. The amendments also require enhanced disclosures about those investments. In accordance with ASU No. 2016-01, we adopted this standard in the first quarter of 2018. The adoption of ASU No. 2016-01 did not have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU No. 2016-02 amends the accounting guidance for leases. The amendments contain principles that will require lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability, unless the lease is a short-term lease that has an accounting lease term of 12 months or less. The amendments also contain other changes to the current lease guidance that may result in changes to how entities determine which contractual arrangements qualify as a lease, the accounting for executory costs (such as property taxes and insurance), as well as which lease origination costs will be capitalizable. The new standard also requires expanded quantitative and qualitative disclosures. ASU No. 2016-02 is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted. ASU No. 2016-02 requires the use of the modified retrospective transition method, whereby the new guidance will be applied at the beginning of the earliest period presented in the financial statements of the period of adoption. We are currently evaluating the impact of ASU No. 2016-02 on our consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash. ASU No. 2016-18 requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. In accordance with ASU No. 2016-18, we adopted this standard in the first quarter of 2018 and retrospectively adjusted the condensed consolidated statement of cash flows for the three months ended March 31, 2017, to conform to the current period’s presentation. The adoption of this ASU did not have a material impact on our consolidated financial statements.  

The following table provides a reconciliation of the components of cash, cash equivalents, and restricted cash reported in our condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows, in thousands:

 

 

 

March 31,

 

 

December 31,

 

 

 

2018

 

 

2017

 

Cash and cash equivalents

 

$

516,141

 

 

$

158,837

 

Restricted cash included in other non-current assets

 

 

863

 

 

 

863

 

Total cash, cash equivalents and restricted cash presented in the condensed

     consolidated statement of cash flows

 

$

517,004

 

 

$

159,700

 

The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.

In May 2017, the FASB issued ASU No. 2017-09, Scope of Modification Accounting. ASU No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. This guidance is to be

9


 

applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, we adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on our consolidated financial statements.

Use of Estimates.

The preparation of financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.

Contingencies.

We disclose information regarding each material claim where the likelihood of a loss contingency is probable or reasonably possible. If a loss contingency is probable and the amount of the loss can be reasonably estimated, we record an accrual for the loss. In such cases, there may be an exposure to potential loss in excess of the amount accrued. The insurance recoveries are recorded in the period when the insurance reimbursement is deemed probable. The ability to predict the ultimate outcome of such matters involves judgments, estimates and inherent uncertainties. The actual outcome of such matters could differ materially from management’s estimates. 

 

 

2. Sale of Manufacturing Operations

On March 31, 2018, Arena GmbH sold the Manufacturing Operations via the Siegfried Transaction. The total sales price for the Manufacturing Operations was approximately CHF 4 million of which approximately CHF 3 million was received in cash in March 2018 with the remaining portion to be received in March 2019, net of any qualifying claims by Siegfried. In the event Siegfried agrees to sell or transfer some or all of the transferred assets to certain third parties on or prior to December 31, 2018, for a consideration in excess of a specified amount, Arena GmbH will be entitled to percentage of such excess amount.

We have retrospectively revised the condensed consolidated statements of operations and cash flows for the three months ended March 31, 2017 to reflect the operations and cash flows of the disposed Manufacturing Operations as discontinued operations. The following table summarizes the results of discontinued operations for the periods presented in the consolidated statements of operations for the three months ended March 31, 2018, and 2017, in thousands:

 

 

 

Three months ended March 31,

 

Revenues

 

2018

 

 

2017

 

Net product sales

 

$

1,129

 

 

$

2,711

 

Other collaboration revenue

 

 

372

 

 

 

1,535

 

Toll manufacturing

 

 

1,006

 

 

 

718

 

Total revenues

 

 

2,507

 

 

 

4,964

 

Costs and expenses

 

 

 

 

 

 

 

 

Cost of product sales

 

 

1,858

 

 

 

2,532

 

Cost of toll manufacturing

 

 

1,411

 

 

 

919

 

Research and development

 

 

 

 

 

167

 

General and administrative

 

 

329

 

 

 

644

 

Other expenses, net

 

 

464

 

 

 

648

 

Total costs and expenses

 

 

4,062

 

 

 

4,910

 

Income (loss) from operations of discontinued operations

 

 

(1,555

)

 

 

54

 

Gain on sale of discontinued operations

 

 

725

 

 

 

 

Income (loss) from discontinued operations

 

$

(830

)

 

$

54

 

 

 

3. Fair Value Disclosures

We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

10


 

We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:

 

Level 1

 

-

 

Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

 

 

 

 

 

Level 2

 

-

 

Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.

 

 

 

 

Level 3

 

-

 

Significant unobservable inputs based on our assumptions.

 

The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:

 

 

 

Fair Value Measurements at March 31, 2018

 

 

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

452,360

 

 

$

452,360

 

 

$

 

 

$

 

US government and government agency notes(2)

 

 

48,126

 

 

 

48,126

 

 

 

 

 

 

 

Corporate debt instruments(2)

 

 

76,849

 

 

 

 

 

 

76,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at December 31, 2017

 

 

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

48,750

 

 

$

48,750

 

 

$

 

 

$

 

US government and government agency notes(2)

 

 

50,335

 

 

 

50,335

 

 

 

 

 

 

 

Corporate debt instruments(2)

 

 

94,639

 

 

 

 

 

 

94,639

 

 

 

 

 

 

(1)

Included in cash and cash equivalents in the accompanying condensed consolidated balance sheets.

 

(2)

Included in either cash and cash equivalents or available-for-sale investments in the accompanying condensed consolidated balance sheets.

 

 

11


 

4. Investments, Available-for-Sale

Investments, available-for-sale, consisted of the following, in thousands:

 

March 31, 2018

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

< 1

 

$

48,158

 

 

$

 

 

$

(32

)

 

$

48,126

 

Corporate debt securities

 

< 1

 

 

65,099

 

 

 

 

 

 

(245

)

 

 

64,854

 

Short-term investments, available-for-sale

 

 

 

$

113,257

 

 

$

 

 

$

(277

)

 

$

112,980

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2017

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

< 1

 

$

34,873

 

 

$

 

 

$

(8

)

 

$

34,865

 

Corporate debt securities

 

< 1

 

 

53,438

 

 

 

 

 

 

(63

)

 

 

53,375

 

Short-term investments, available-for-sale

 

 

 

$

88,311

 

 

$

 

 

$

(71

)

 

$

88,240

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

1 – 5

 

 

24,304

 

 

 

 

 

 

(62

)

 

 

24,242

 

Investments, available-for-sale

 

 

 

$

24,304

 

 

$

 

 

$

(62

)

 

$

24,242

 

 

 

5. Land, Property and Equipment

Land, property and equipment consisted of the following, in thousands:

 

 

 

March 31,

 

 

December 31,

 

 

 

2018

 

 

2017

 

Cost

 

$

88,570

 

 

$

88,244

 

Less accumulated depreciation and amortization

 

 

(59,063

)

 

 

(58,113

)

Land, property and equipment, net

 

$

29,507

 

 

$

30,131

 

 

 

6. Accounts Payable and Other Accrued Liabilities

Accounts payable and other accrued liabilities consisted of the following, in thousands:

 

 

 

March 31,

 

 

December 31,

 

 

 

2018

 

 

2017

 

Accounts payable

 

$

4,419

 

 

$

1,599

 

Accrued compensation

 

 

2,605

 

 

 

5,255

 

Other accrued liabilities

 

 

2,087

 

 

 

1,062

 

Total accounts payable and other accrued liabilities

 

$

9,111

 

 

$

7,916

 

 

 

7. Collaborations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2017, for a full description of our significant collaboration agreements.

Eisai.

In July 2010, we granted Eisai exclusive commercialization rights for lorcaserin (branded as BELVIQ and BELVIQ XR) solely in the United States and its territories and possessions. In May 2012, we and Eisai entered into the first amended and restated agreement, which expanded Eisai’s exclusive commercialization rights to include most of North and South America. In

12


 

November 2013, we and Eisai entered into the second amended and restated agreement, which expanded Eisai’s exclusive commercialization rights for lorcaserin to all of the countries in the world, except for South Korea, Taiwan, Australia, New Zealand and Israel.

In December 2016, we and Eisai amended and restated the terms of the marketing and supply agreement for lorcaserin with Eisai by entering into a Transaction Agreement and a Supply Agreement (collectively, the Eisai Agreement) with Eisai. Under the Transaction Agreement, Eisai acquired an exclusive royalty-bearing license or transfer of intellectual property to global commercialization and manufacturing rights to lorcaserin, including in the territories retained by us under the prior agreement, with control over global development and commercialization decisions. Eisai is responsible for all lorcaserin development expenses going forward. We also assigned to Eisai our rights under the commercial lorcaserin distribution agreements with Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea; CY Biotech Company Limited, or CYB, for Taiwan; and Teva Pharmaceuticals Ltd.’s Israeli subsidiary, Abic Marketing Limited, or Teva, for Israel.

Under the Supply Agreement, Eisai paid us $10.0 million in December 2016 to acquire our entire on-hand inventory of bulk lorcaserin and the precursor material for manufacturing lorcaserin. Eisai also paid us for finished drug product plus monthly manufacturing support payments through March 2018 totaling CHF 8.7 million.

Until March 31, 2018, when we sold the Manufacturing Operations, including the assignment of the Supply Agreement, to Siegfried (see Note 2), we manufactured lorcaserin at our manufacturing facility in Zofingen, Switzerland. Revenues earned for (i) lorcaserin sold by us to Eisai under the manufacturing and supply commitment within the Supply Agreement and (ii) the manufacturing support payments are classified within discontinued operations as part of the Manufacturing Operations in the condensed consolidated statements of operations (see Note 2). All other revenues earned under the Transaction Agreement, such as royalties, are classified within continuing operations in the condensed consolidated statements of operations.

Royalty payments.

Pursuant to the Transaction Agreement, we are eligible to receive royalty payments from Eisai based on the global net sales of lorcaserin. The royalty rates are as follows:

 

9.5% on annual net sales less than or equal to $175.0 million

 

13.5% on annual net sales greater than $175.0 million but less than or equal to $500.0 million

 

18.5% of annual net sales greater than $500.0 million

Upfront payments.

Prior to the Transaction Agreement, we received from Eisai total upfront payments of $115.0 million under prior lorcaserin collaboration agreements and $7.5 million from the prior commercial lorcaserin distribution agreements with Ildong, CYB, and Teva. Revenues from these upfront payments were previously deferred, as we determined that the exclusive rights did not have standalone value without our ongoing development and regulatory activities. Accordingly, these payments were recognized ratably as revenue over the periods in which we expected the services to be rendered.

Milestone payments.

Prior to the Transaction Agreement, we received a total of $102.1 million in milestone payments from Eisai, Ildong, CYB, and Teva. These payments were recognized as revenue upon the achievement of the milestones.

We are eligible to receive an additional sales-based milestone of $25.0 million upon the achievement of global net sales of lorcaserin for a calendar year first exceeding $250.0 million.

Accounting for Eisai Agreement under ASC 606.

Upon implementation of ASC 606 on January 1, 2018, we applied a practical expedient for contract modifications applicable to contracts that were modified before the implementation date. The promised goods and services under the Eisai Agreement were assessed in combination with promised goods and services under our previous agreements with Eisai and commercial lorcaserin distribution agreements with Ildong, CYB, and Teva. The total estimated transaction price of these contracts at the implementation date was $344.4 million, which included previously received upfront payments, milestone payments, proceeds from net products sales, reimbursement of development expenses, reimbursement of patent expenses, manufacturing support payments received and expected

13


 

to be received under the Supply Agreement, proceeds from the sale of on-hand inventory of bulk lorcaserin and the precursor material, royalty payments received through December 31, 2017, and estimated future royalty payments related to intellectual property sold to Eisai. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained due to our assessment of the probability of a significant revenue reversal. The future royalties related to licensed intellectual property were excluded from the estimated total transaction price under the royalty exception in ASC 606. The future royalties that relate to intellectual property sold to Eisai do not qualify for the royalty exception in ASC 606 and were included in the estimated total transaction price.

The estimated total transaction price was allocated between satisfied and unsatisfied performance obligations based on the relative standalone selling prices of the identified performance obligations. The remaining manufacturing and supply obligations under the Supply Agreement was the only unsatisfied performance obligation. As a result of this allocation, on January 1, 2018, we reduced the balance of deferred revenues associated with the Eisai Agreement at the implementation date by $25.5 million, recognized a contract asset of $6.1 million related to future manufacturing support payments under the Supply Agreement and recognized a contract asset of $4.1 million related to estimated future royalty payments from intellectual property sold to Eisai under the Transaction Agreement. In connection with the sale of the Manufacturing Operations on March 31, 2018, we derecognized the remaining portion of the contract asset associated with the Supply Agreement.

Based on the bill-and-hold accounting guidance in ASC 606, effective January 1, 2018, we derecognized $3.6 million of inventory of bulk lorcaserin and the precursor material previously sold to Eisai for which the revenue recognition criteria were met on the implementation date under ASC 606.

For the three months ended March 31, 2018, we recorded royalty revenue of $0.7 million related to the Transaction Agreement with no corresponding revenue for the three months ended March 31, 2017. For the three months ended March 31, 2018 and 2017, we recognized as revenue $1.5 million and $4.2 million (classified under discontinued operations), respectively, related to the Supply Agreement and primarily consisting of net product sales and other collaboration revenue.

In the condensed consolidated balance sheet at December 31, 2017, the deferred revenues of $25.5 million relating to the Eisai Agreement (primarily comprised of the deferred portion of the previously received upfront payments and the $10.0 million payment received from Eisai in December 2016) were classified as liabilities of disposal group held for sale.

Axovant Sciences GmbH.

We and Axovant have a development, marketing and supply agreement, or Axovant Agreement, under which Axovant has exclusive worldwide rights to develop and commercialize nelotanserin, subject to regulatory approval. We also provide certain services, including manufacturing, and will sell nelotanserin to Axovant.

Under the Axovant Agreement, we received an upfront payment of $4.0 million in May 2015. We will receive payments from potential sales of nelotanserin under the Axovant Agreement and are eligible to receive purchase price adjustment payments based on Axovant’s annual net product sales. We are eligible to receive up to an aggregate of $41.5 million in success milestone payments in case of full development and regulatory success of nelotanserin.

The promised goods and services under the Axovant Agreement are accounted for as two separate performance obligations: (i) a combined performance obligation consisting of commercialization rights and development and regulatory services and (ii) a manufacturing and supply commitment. As of March 31, 2018, the estimated total transaction price was $10.2 million, of which $4.1 million is associated with performance obligations to be satisfied in the future. The future potential purchase price adjustment payments and milestone payments were excluded from the estimated total transaction price as they are considered constrained. We recognize revenue for the combined performance obligation consisting of commercialization rights and development and regulatory services based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

For the three months ended March 31, 2018 and 2017, we recorded revenue of $0.6 million and $0.4 million, respectively, related to the Axovant Agreement.

Boehringer Ingelheim International GmbH.

We and Boehringer Ingelheim have a collaboration and license agreement, or Boehringer Ingelheim Agreement, to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor, or GPCR, that belongs to the group of orphan central nervous system, or CNS, receptors. The Boehringer Ingelheim Agreement was in effect through January 2018. We and

14


 

Boehringer Ingelheim agreed to extend the original term of the Boehringer Ingelheim Agreement by twelve months through January 2019.

In partial consideration of the exclusive rights to our intellectual property necessary or useful to conduct the joint research under the Boehringer Ingelheim Agreement, we received from Boehringer Ingelheim an upfront payment of $7.5 million in 2016. Under the Boehringer Ingelheim Agreement, we are eligible to receive up to an aggregate of $251.0 million in success milestone payments in case of full commercial success of multiple drug products.

The promised goods and services under the Boehringer Ingelheim Agreement are accounted for as a single combined performance obligation consisting of a research license, a development and commercialization license and research services. Our performance obligation under the original term of the Boehringer Ingelheim Agreement was fully satisfied as of March 31, 2018, so the estimated total transaction price of the Boehringer Ingelheim Agreement under the original contractual term of $10.5 million was fully recognized as revenue over the period from January 2016 through March 2018. As of March 31, 2018, the estimated total transaction price associated with the extended term of the Boehringer Ingelheim Agreement was $0.7 million, of which $0.6 million is associated with performance obligations to be satisfied in the future. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained. We recognize revenue for the combined performance obligation based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

For the three months ended March 31, 2018 and 2017, we recorded revenue of $0.5 million and $1.2 million, respectively, related to the Boehringer Ingelheim Agreement.

 

 

8. Stockholders’ Equity

In March 2018, we completed the sale of an aggregate of 9,775,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $383.1 million after deducting underwriting discounts and commissions and offering expenses payable by us. 

9. Share-based Compensation

We recognized share-based compensation expense as follows, in thousands:

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2018

 

 

2017

 

Research and development

 

$

1,650

 

 

$

379

 

General and administrative

 

 

2,383